Wednesday, February 10, 2010, 10:22pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Alnylam Pharmaceuticals, Inc. (ALNY)

At 5:00AM SGT: 16.93 USD   0.00 (0.00%)  
 MORE ON ALNY 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Alnylam Pharmaceuticals, Inc. (NasdaqNM:ALNY) Delayed quote dataEdit
Last Trade:16.93 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:16.93
Open:N/A
Bid:16.39 x 100
Ask:17.44 x 100
1y Target Est:26.17
Day's Range:N/A - N/A
52wk Range:14.82 - 24.75
Volume:0
Avg Vol (3m):246,703
Market Cap:707.93M
P/E (ttm):N/A
EPS (ttm):-1.19
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ALNY to Portfolio   Download Data

 HEADLINES 
•Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
Business Wire (Mon, Feb 8)
•Alnylam to Webcast Presentation at The 12th Annual BIO CEO & Investor Conference
Business Wire (Tue, Feb 2)
•Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
Business Wire (Mon, Jan 25)
•The Noble Gesture That Wasn't
at Motley Fool (Fri, Jan 22)
•BIO Ventures for Global Health Chosen as Administrator of Intellectual Property Pool Involving GSK and Alnylam as Participants
Business Wire (Wed, Jan 20)
•Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
Business Wire (Wed, Jan 20)
•Alnylam and Collaborators Discover Additional Class of Novel Lipid Nanoparticles with Markedly Improved In Vivo Potency for RNAi Therapeutics
Business Wire (Tue, Jan 19)
•Alnylam's Kreutzer-Limmer I Patent Upheld in German Opposition Proceedings
Business Wire (Fri, Jan 15)
•Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
Business Wire (Fri, Jan 15)
•Alnylam Pharma Guides
Zacks.com (Thu, Jan 14)
•Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Business Wire (Mon, Jan 11)
More Headlines for ALNY...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.26
EPS Est (in 2 years) (Dec-10) :-1.44
Avg Rec (current)*:2.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi).

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices